TriCelX wins FDA clearance for first CTE cell therapy trial

TriCelX says the FDA has authorized a Phase 1/2 trial of XytriX in chronic traumatic encephalopathy under IND 32912, making it the first cell therapy to be studied in the disease. The trial is aimed at blast-exposed service members, veterans and former contact-sport athletes with probable CTE.

Why it matters: - The FDA clearance opens the first cell therapy trial ever studied in chronic traumatic encephalopathy, a disease with no approved treatment. - The trial targets two groups hit hardest by repeated head trauma: blast-exposed service members and veterans, and former contact-sport athletes. - TriCelX is positioning XytriX as a potential option for a condition linked to chronic neuroinflammation and tau pathology.

What happened: - TriCelX announced that the U.S. Food and Drug Administration authorized its Phase 1/2 clinical trial of XytriX to proceed under IND 32912. - The company says the study is the first time a cell therapy will be investigated in CTE. - The announcement was made June 15, 2026, from Frisco, Texas.

The details: - The trial is an open-label, three-cohort dose-escalation study using a 3+3 design. - XytriX is an allogeneic human umbilical cord-derived mesenchymal stem cell therapy given intravenously and intrathecally. - Eligible participants must be adults with probable CTE and a clinician diagnosis of Traumatic Encephalopathy Syndrome at the probable level under the 2021 NINDS TES criteria. - The study will assess safety and tolerability through treatment-emergent and serious adverse events and dose-limiting toxicities. - Researchers will also track preliminary efficacy through changes in validated neurocognitive, behavioral and functional outcomes over 24 months. - Exploratory measures include serum neurofilament light chain, GFAP, plasma phosphorylated-tau species, structural MRI, DTI and functional MRI. - The protocol includes scheduled lumbar-spine MRI surveillance for the intrathecal cohort. - TriCelX says the trial will enroll adults across the two communities most affected by the disease.

Between the lines: - The company is framing the program as both a medical advance and a symbolic response to a long-running treatment gap for military and sports-related brain injury. - TriCelX says the trial is the foundational study for how later cell therapy programs in CTE will be measured. - The company also ties the program to the Blast Overpressure Safety Act of December 2024 and DoD Instruction 6200.02, which it says support blast TBI and CTE countermeasures and Expanded Access during development. - TriCelX says it is engaging the U.S. Army Medical Materiel Development Activity, NIH/NINDS and the National Intrepid Center of Excellence.

What's next: - The study will test safety, tolerability and early signals of efficacy over a 24-month period. - TriCelX plans to use biomarker and imaging data to inform a later controlled trial. - The company says XytriX is also in Phase 1/2 development for knee osteoarthritis under an IND filed March 30, 2026. - TriCelX says additional indications are planned across neurology, immunology and orthopedics.

The bottom line: - TriCelX has moved XytriX into the clinic for a first-of-its-kind CTE trial, giving the company a regulatory green light in a disease where treatment options remain absent.